BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 17228021)

  • 21. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
    Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
    Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach.
    De Sanctis V; Martelli M; Anticoli AP; Caronna R; Chirletti P; Giovannini M; Santarelli M; Enrici RM; Mandelli F
    Anticancer Res; 2001; 21(6A):4169-72. PubMed ID: 11911313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New treatment options have changed the survival of patients with follicular lymphoma.
    Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP
    J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
    Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
    Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
    Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
    Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
    Brusamolino E; Rusconi C; Montalbetti L; Gargantini L; Uziel L; Pinotti G; Fava S; Rigacci L; Pagnucco G; Pascutto C; Morra E; Lazzarino M
    Haematologica; 2006 Apr; 91(4):496-502. PubMed ID: 16537117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
    Tsukasaki K; Utsunomiya A; Fukuda H; Shibata T; Fukushima T; Takatsuka Y; Ikeda S; Masuda M; Nagoshi H; Ueda R; Tamura K; Sano M; Momita S; Yamaguchi K; Kawano F; Hanada S; Tobinai K; Shimoyama M; Hotta T; Tomonaga M;
    J Clin Oncol; 2007 Dec; 25(34):5458-64. PubMed ID: 17968021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte.
    van der Kaaij MA; Heutte N; Le Stang N; Raemaekers JM; Simons AH; Carde P; Noordijk EM; Fermé C; Thomas J; Eghbali H; Kluin-Nelemans HC; Henry-Amar M; ;
    J Clin Oncol; 2007 Jul; 25(19):2825-32. PubMed ID: 17515571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen].
    Huang HQ; Peng YL; Lin XB; Sun XF; Lin TY; Xia ZJ; Li YH; Cai QQ; He YJ; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1443-7. PubMed ID: 15566653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
    Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA
    Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma.
    Niitsu N; Okamoto M; Aoki S; Okumura H; Yoshino T; Miura I; Hirano M
    Ann Hematol; 2006 Jun; 85(6):374-80. PubMed ID: 16518603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.
    Marcus R; Imrie K; Solal-Celigny P; Catalano JV; Dmoszynska A; Raposo JC; Offner FC; Gomez-Codina J; Belch A; Cunningham D; Wassner-Fritsch E; Stein G
    J Clin Oncol; 2008 Oct; 26(28):4579-86. PubMed ID: 18662969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma.
    Burton C; Smith P; Vaughan-Hudson G; Qian W; Hoskin P; Cunningham D; Hancock B; Linch D
    Br J Haematol; 2005 Aug; 130(4):536-41. PubMed ID: 16098067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.
    Laack NN; Ballman KV; Brown PB; O'Neill BP;
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1429-39. PubMed ID: 16863926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.
    Horning SJ; Weller E; Kim K; Earle JD; O'Connell MJ; Habermann TM; Glick JH
    J Clin Oncol; 2004 Aug; 22(15):3032-8. PubMed ID: 15210738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.
    Rueda A; Sabin P; Rifá J; Llanos M; Gómez-Codina J; Lobo F; García R; Herrero J; Provencio M; Jara C;
    Hematol Oncol; 2008 Mar; 26(1):27-32. PubMed ID: 17868190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
    Besson C; Canioni D; Lepage E; Pol S; Morel P; Lederlin P; Van Hoof A; Tilly H; Gaulard P; Coiffier B; Gisselbrecht C; Brousse N; Reyes F; Hermine O;
    J Clin Oncol; 2006 Feb; 24(6):953-60. PubMed ID: 16418500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma.
    De Sanctis V; Finolezzi E; Osti MF; Grapulin L; Alfò M; Pescarmona E; Berardi F; Natalino F; Moleti ML; Di Rocco A; Enrici RM; Foà R; Martelli M
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1154-60. PubMed ID: 18472357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II study.
    Cocconi G; Franciosi V; Dodero A; Bologna A; Vasini G; De Lisi V; Di Blasio B; Ceci G; Camisa R; Cascinu S
    Am J Clin Oncol; 2003 Dec; 26(6):535-42. PubMed ID: 14663368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
    Djunic I; Jevtovic DL; Ranin J; Salemovic D; Tomin D; Mihaljevic B
    Biomed Pharmacother; 2008 Jan; 62(1):12-5. PubMed ID: 17629445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.